Skip to content
  • EN
  • فا
  • EN
  • فا
  • COMPANY
    • RESPONSIBILITY
    • OUR PARTNERS
    • ABOUT US
  • PRODUCTS
  • NEWS
  • Actero Support
    • Physician
    • Nurse Support
    • Patient Support
    • Adverse Drug Reactions
  • CONTACT
    • CONTACT US
    • JOIN US
  • COMPANY
    • RESPONSIBILITY
    • OUR PARTNERS
    • ABOUT US
  • PRODUCTS
  • NEWS
  • Actero Support
    • Physician
    • Nurse Support
    • Patient Support
    • Adverse Drug Reactions
  • CONTACT
    • CONTACT US
    • JOIN US

Archives

Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non-small cell lung cancer

Innovative Approaches to the Management of Acute Lymphoblastic Leukemia Across the Age Spectrum

Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis

Fear of Cancer Recurrence or Progression: What Is It and What Can We Do About It?

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study

← Previous
Next →

HEADQUARTERS

Address : No.145-146, Ronika Palace, East Gharavi, Ashrafi Esfahani •1476785534 • Tehran • Iran

Telefax: +98 (21) 44348411 – 15
Email: info@acteropharma.com

PRODUCTION FACILITY

Address: On the corner of 8th Golestan Blvd., Baharestan Industrial Zone, Karaj

Telefax: +98 (26) 34760951-2

Related Links

  • Actoverco Website
  • Hematology and Oncology Society of Iran
  • Iranian Society of Clinical Oncology (ISCO)
  • Congress of Urinary Tract Cancers
  • Actoverco Website
  • Hematology and Oncology Society of Iran
  • Iranian Society of Clinical Oncology (ISCO)
  • Congress of Urinary Tract Cancers
Instagram Linkedin

© 2025 Actero. ALL RIGHTS RESERVED.